ATRT Investigators -


Sarah Leary, MD

Seattle Children’s Hospital [Seattle, WA]

Sarah Leary, MD, is an attending physician in the Cancer and Blood Disorders Center at Seattle Children's Hospital and Associate Professor of Pediatrics at the University of Washington School of Medicine. Her clinical and research focus is in the area of pediatric brain tumors.

Locally, she serves on the Tumor Tissue Subcommittee and the Research Review Committee; Nationally, she is leading several clinical trials to study new medications for children with brain tumors at Seattle Children's Hospital, through the Children's Oncology Group, the Pacific Pediatric Neuro-Oncology Consortium (PNOC)and the Pediatric Brain Tumor Consortium (PBTC). Dr. Leary works with laboratory investigators at the Fred Hutchinson Cancer Research Center and the Seattle Children's Research Institute as well as the Pathology Department at Seattle Children's Hospital to identify novel therapeutic targets and tests. The goal of her clinical and translational research is to improve outcomes for brain tumor patients by developing biologically targeted therapeutics.

Investigator of Clinical Trials:  


Nicholas Vitanza, MD

Seattle Children’s Hospital [Seattle, WA]

Dr. Nicholas Vitanza is a pediatric neuro-oncologist at Seattle Children’s Hospital and a research scientist at the Fred Hutchinson Cancer Research Center in Seattle, Washington, USA. In clinic, he cares for children with central nervous system (CNS) tumors and, in the lab, he studies diffuse intrinsic pontine glioma (DIPG). His prior work has illuminated the transcriptional dependencies of DIPG and identified novel agents, as well as combinatorial treatment strategies, that have entered clinical trials. His current research aims to identify critical vulnerabilities within DIPG that can be targeted both molecularly and immunotherapeutically, with the hope of improving outcomes for affected children. He also serves as the CNS CAR T cell Lead and is the PI of BrainChild-01, a locoregional CAR T cell trial targeting HER2 for children with recurrent/refractory CNS tumors, and BrainChild-03, a locoregional CAR T cell trial targeting B7-H3 for children with recurrent/refractory CNS tumors and DIPG.


Nicholas A. Vitanza, MD

Assistant Professor & Pediatric Neuro-Oncologist, Seattle Children’s Hospital

CNS CAR T Cell Lead, Seattle Children’s Research Institute

Affiliate Investigator, Fred Hutchinson Cancer Research Center

PI of Clinical Trials: